Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse
BACKGROUND: In hepatitis C virus (HCV)/HIV-coinfected patients who failed a course of suboptimal hepatitis C therapy, retreatment with adequate doses and duration of pegylated interferon (pegIFN) plus ribavirin (RBV) is advisable in the presence of compensated advanced liver fibrosis.
METHODS: The efficacy and safety of pegIFN-alpha2a (180 microg/wk) plus RBV (<75 kg: 1000 mg/d; > or = 75 kg: 1200 mg/d) given for 12 months was prospectively assessed in HIV/HCV patients with nonresponse or relapse to a prior course of suboptimal hepatitis C therapy. The main endpoint was the achievement of sustained virological response (SVR).
RESULTS: A total of 52 patients were enrolled in the study (78% HCV genotypes 1 or 4; 56% with advanced liver fibrosis). Prior suboptimal regimens were IFN monotherapy (20%), IFN plus RBV (29%), and pegIFN plus RBV 800 mg/d (51%). Overall, 61% were nonresponders and 39% relapsers. Retreatment provided SVR in 30.8% of patients (19.5% for genotypes 1/4 vs. 72.7% for genotypes 2/3; P = 0.002). In multivariate analysis, HCV genotypes 2/3 [OR 22.2, 95% confidence interval (CI), 2.9-166.7, P = 0.003] and RBV plasma trough concentrations at week 4 [OR 3.9 (95% CI, 1.3-11.8), P = 0.01] were the only independent predictors of SVR.
CONCLUSIONS: Retreatment with pegIFN-alpha2a plus weight-based RBV for 12 months permits to achieve HCV clearance in nearly onethird of HIV/HCV-coinfected patients who failed a prior suboptimal course of hepatitis C therapy. Patients with HCV genotypes 2/3 and those with RBV plasma trough levels above 2.07 microg/mL show the highest chances of SVR.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2010 |
---|---|
Erschienen: |
2010 |
Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
---|---|
Enthalten in: |
Journal of acquired immune deficiency syndromes (1999) - 53(2010), 3 vom: 26. März, Seite 364-8 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Labarga, Pablo [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.03.2010 Date Revised 30.09.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/QAI.0b013e3181bd5ce1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM194609790 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM194609790 | ||
003 | DE-627 | ||
005 | 20231223201059.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231223s2010 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/QAI.0b013e3181bd5ce1 |2 doi | |
028 | 5 | 2 | |a pubmed24n0649.xml |
035 | |a (DE-627)NLM194609790 | ||
035 | |a (NLM)20101191 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Labarga, Pablo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse |
264 | 1 | |c 2010 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.03.2010 | ||
500 | |a Date Revised 30.09.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: In hepatitis C virus (HCV)/HIV-coinfected patients who failed a course of suboptimal hepatitis C therapy, retreatment with adequate doses and duration of pegylated interferon (pegIFN) plus ribavirin (RBV) is advisable in the presence of compensated advanced liver fibrosis | ||
520 | |a METHODS: The efficacy and safety of pegIFN-alpha2a (180 microg/wk) plus RBV (<75 kg: 1000 mg/d; > or = 75 kg: 1200 mg/d) given for 12 months was prospectively assessed in HIV/HCV patients with nonresponse or relapse to a prior course of suboptimal hepatitis C therapy. The main endpoint was the achievement of sustained virological response (SVR) | ||
520 | |a RESULTS: A total of 52 patients were enrolled in the study (78% HCV genotypes 1 or 4; 56% with advanced liver fibrosis). Prior suboptimal regimens were IFN monotherapy (20%), IFN plus RBV (29%), and pegIFN plus RBV 800 mg/d (51%). Overall, 61% were nonresponders and 39% relapsers. Retreatment provided SVR in 30.8% of patients (19.5% for genotypes 1/4 vs. 72.7% for genotypes 2/3; P = 0.002). In multivariate analysis, HCV genotypes 2/3 [OR 22.2, 95% confidence interval (CI), 2.9-166.7, P = 0.003] and RBV plasma trough concentrations at week 4 [OR 3.9 (95% CI, 1.3-11.8), P = 0.01] were the only independent predictors of SVR | ||
520 | |a CONCLUSIONS: Retreatment with pegIFN-alpha2a plus weight-based RBV for 12 months permits to achieve HCV clearance in nearly onethird of HIV/HCV-coinfected patients who failed a prior suboptimal course of hepatitis C therapy. Patients with HCV genotypes 2/3 and those with RBV plasma trough levels above 2.07 microg/mL show the highest chances of SVR | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Interferon alpha-2 |2 NLM | |
650 | 7 | |a Interferon-alpha |2 NLM | |
650 | 7 | |a RNA, Viral |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
650 | 7 | |a Polyethylene Glycols |2 NLM | |
650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
650 | 7 | |a Ribavirin |2 NLM | |
650 | 7 | |a 49717AWG6K |2 NLM | |
650 | 7 | |a peginterferon alfa-2a |2 NLM | |
650 | 7 | |a Q46947FE7K |2 NLM | |
700 | 1 | |a Vispo, Eugenia |e verfasserin |4 aut | |
700 | 1 | |a Barreiro, Pablo |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez-Novoa, Sonia |e verfasserin |4 aut | |
700 | 1 | |a Pinilla, Javier |e verfasserin |4 aut | |
700 | 1 | |a Morello, Judit |e verfasserin |4 aut | |
700 | 1 | |a Martín-Carbonero, Luz |e verfasserin |4 aut | |
700 | 1 | |a Tuma, Paula |e verfasserin |4 aut | |
700 | 1 | |a Medrano, José |e verfasserin |4 aut | |
700 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of acquired immune deficiency syndromes (1999) |d 1999 |g 53(2010), 3 vom: 26. März, Seite 364-8 |w (DE-627)NLM101679912 |x 1944-7884 |7 nnns |
773 | 1 | 8 | |g volume:53 |g year:2010 |g number:3 |g day:26 |g month:03 |g pages:364-8 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAI.0b013e3181bd5ce1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 53 |j 2010 |e 3 |b 26 |c 03 |h 364-8 |